
  
    
      
        
        Before_IN insulin_NN was_VBD discovered_VBN and_CC purified_JJ ,_, doctors_NNS could_MD only_RB watch_VB as_IN their_PRP$ patients_NNS
        slowly_RB died_VBD of_IN type_NN 1_CD diabetes_NN mellitus_JJ ._. In_IN January_NNP 1922_CD ,_, the_DT prognosis_NN was_VBD changed_VBN
        dramatically_RB when_WRB a_DT teenager_NN with_IN diabetes_NN in_IN a_DT Toronto_NNP hospital_NN became_VBD the_DT first_JJ recorded_VBN
        recipient_NN of_IN an_DT injection_NN of_IN insulin_NN ._. Although_IN this_DT preparation_NN was_VBD far_RB from_IN perfect_JJ ,_, as_IN
        Frederick_NNP Banting_NNP said_VBD in_IN his_PRP$ Nobel_NNP lecture_NN of_IN 1925_CD (_( Nobel_NNP laureates_NNS did_VBD not_RB have_VB to_TO wait_VB
        so_RB long_RB as_IN they_PRP do_VBP now_RB for_IN recognition_NN )_) ,_, “ There_EX was_VBD a_DT marked_VBN reduction_NN in_IN blood_NN sugar_NN and_CC
        the_DT urine_NN was_VBD rendered_VBN sugar_NN free_JJ ._.” Suddenly_RB diabetes_NN was_VBD a_DT potentially_RB curable_JJ disease_NN ._.
        But_CC insulin_NN 's_POS very_RB success_NN brought_VBD trouble_NN ,_, as_IN demand_NN far_RB exceeded_VBD the_DT supply_NN ._.
        Now_RB recombinant_JJ insulin_NN is_VBZ available_JJ in_IN plentiful_JJ supply_NN ,_, but_CC the_DT control_NN of_IN type_NN 1_CD
        diabetes_NN remains_VBZ far_RB from_IN perfect_JJ ,_, and_CC researchers_NNS have_VBP looked_VBN towards_IN an_DT ideal_NN of_IN
        transplanting_VBG insulin-producing_JJ cells_NNS instead_RB ._. The_DT best_JJS protocol_NN for_IN this_DT ,_, also_RB pioneered_VBD
        in_IN Canada_NNP ,_, the_DT Edmonton_NNP protocol_NN ,_, uses_VBZ ß-cells_JJ isolated_VBN from_IN human_JJ cadavers_NNS and_CC has_VBZ shown_VBN
        some_DT remarkable_JJ results_NNS with_IN around_IN 84_CD %_NN of_IN patients_NNS remaining_VBG insulin-free_JJ after_IN one_CD year_NN
        and_CC 89_CD %_NN of_IN patients_NNS still_RB producing_VBG insulin_NN after_IN three_CD years_NNS ._. However_RB ,_, the_DT isolation_NN of_IN
        ß-cells_JJ is_VBZ laborious_JJ and_CC limited_VBN by_IN donor_NN availability_NN ._.
        The_DT next_JJ logical_JJ step_NN ,_, then_RB ,_, is_VBZ to_TO look_VB for_IN renewable_JJ sources_NNS of_IN insulin-producing_JJ
        cells_NNS ._. The_DT emerging_VBG science_NN of_IN human_JJ stem_NN cell_NN research_NN makes_VBZ this_DT step_NN possible_JJ ,_, and_CC in_IN a_DT
        paper_NN in_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP Seung_NNP Kim_NNP and_CC colleagues_NNS from_IN Stanford_NNP University_NNP suggest_VBP
        that_IN researchers_NNS should_MD look_VB beyond_IN just_RB pancreatic_JJ precursors_NNS and_CC embryonic_JJ stem_NN cells_NNS to_TO
        other_JJ cell-type_JJ precursors_NNS for_IN ideas_NNS about_IN ß-cell_JJ replacement_NN ._.
        The_DT rationale_NN for_IN the_DT approach_NN in_IN this_DT study_NN comes_VBZ from_IN observations_NNS that_IN although_IN the_DT
        pancreatic_JJ islet_NN cells_NNS are_VBP the_DT principal_JJ source_NN of_IN insulin_NN in_IN humans_NNS ,_, in_IN some_DT invertebrate_NN
        species_NNS ,_, such_JJ as_IN 
        Drosophila_NNP ,_, most_JJS circulating_VBG insulin_NN is_VBZ produced_VBN by_IN brain_NN
        neurons_NNS ._. Intriguingly_NNP ,_, the_DT gene_NN encoding_VBG insulin_NN is_VBZ also_RB transcribed_JJ by_IN some_DT vertebrate_NN
        neurons—although_NN it_PRP is_VBZ not_RB clear_JJ whether_IN they_PRP then_RB produce_VBP or_CC secrete_NN insulin_NN protein_NN ._.
        Kim_NNP and_CC colleagues_NNS took_VBD human_JJ neural_NN progenitor_NN cells_NNS derived_VBN from_IN brain_NN ,_, and_CC exposed_VBD
        them_PRP to_TO a_DT series_NN of_IN signals_NNS that_WDT are_VBP known_VBN to_TO drive_VB pancreatic_JJ islet_NN development_NN ._. They_PRP were_VBD
        able_JJ to_TO produce_VB clusters_NNS of_IN insulin-producing_JJ cells_NNS that_WDT were_VBD responsive_JJ to_TO glucose_NN in_IN
        vitro_NN ._. After_IN transplantation_NN into_IN immunocompromised_JJ mice_NNS ,_, circulating_VBG human_JJ insulin_NN and_CC
        C-_NNP peptide_NN derived_VBN from_IN the_DT proinsulin_NN precursor_NN were_VBD detected_VBN when_WRB the_DT mice_NNS were_VBD given_VBN
        glucose_NN ._.
        Of_IN course_NN ,_, results_NNS in_IN mice_NNS do_VBP not_RB mean_VB that_IN such_JJ treatments_NNS would_MD automatically_RB work_VB in_IN
        humans_NNS ,_, and_CC before_IN any_DT such_JJ therapies_NNS become_VBP available_JJ there_EX are_VBP many_JJ hurdles_NNS to_TO overcome_VB ._.
        Some_DT of_IN the_DT most_RBS important_JJ include_VBP the_DT long-term_JJ stability_NN and_CC safety_NN of_IN the_DT cells_NNS
        (_( although_IN the_DT cells_NNS remained_VBD differentiated_JJ in_IN the_DT mice_NNS and_CC did_VBD not_RB form_VB tumors_NNS ,_, such_JJ a_DT
        risk_NN would_MD need_VB to_TO be_VB very_RB thoroughly_RB investigated_VBN because_IN of_IN the_DT chronic_JJ nature_NN of_IN
        diabetes_NN )_) ,_, and_CC how_WRB to_TO scale_VB up_RP such_JJ a_DT process_NN to_TO produce_VB the_DT much_RB larger_JJR numbers_NNS of_IN cells_NNS
        needed_VBN for_IN human_JJ treatment_NN ._. Nonetheless_RB ,_, work_NN like_IN this_DT study_NN from_IN Kim_NNP 's_POS group_NN might_MD point_VB
        to_TO where_WRB the_DT future_NN of_IN diabetes_NN treatment_NN lies_NNS ._.
      
    
  
